Clinically Validated Technologies
Advancing Global Health
The Vitamin K2 Expert
NattoPharma is dedicated to delivering premium products proven beneficial for human health through extensive clinical study. This commitment has created patented intellectual properties that provide companies with unsurpassed opportunities to revolutionize their markets.
NattoPharma ASA is listed on Oslo Axess at Oslo Børs under the ticker “Natto”.
NattoPharma delivers novel health ingredients and technologies that are clinically validated to provide optimal health outcomes.
Lesaffre is launching recommended voluntary cash offer for NattoPharma at NOK 35 per share.
NattoPharma ASA is launching cash tender offer to acquire 100% of the shares of Kaydence Pharma AS at an offer price of NOK 5 per share.